Sign in

NCT06663163Completed

The Association Between Fever and CDKL5 Deficiency Disorder: a Nationwide Survey

Source: ClinicalTrials.gov · Last updated 14 Apr 2026

Brief summary (registry, in English)

The primary objective of this research is to study the effects of fever on seizure activity in patients with CDKL5 deficiency disorder

Status (registry)
Completed
Study type
Observational
Enrollment
131 (actual)
First submitted
27 Oct 2024
Start date
29 Oct 2024
Primary completion date
15 Dec 2024
Lead sponsor
Xuanwu Hospital, Beijing
Diseases
Epilepsy
NCT number
NCT06663163

What you commit to

  • Study type: Observational
  • Participants enrolled: 131
  • From 29 Oct 2024 to the primary completion date, 15 Dec 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Any history of previous brain disease (trauma, etc.) that likely to precipitate seizures.

Other illness

  • Presence of any clinical condition that in the opinion of the principal investigator makes the patient not suitable to participate in the trial.

Who the study is looking for

  • A diagnosis of CDKL5 deficiency, including molecular confirmation of a pathogenic or likely pathogenic CDKL5 variant and refractory seizures.
  • Parents or guardians are willing to complete and provide information about the child's medical history and fever history after receiving the survey questionnaire online.

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Xuanwu Hospital, Capital Medical University
Coordinator of this site? Confirm its status
BeijingChinaUnknown status

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.